Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis

British Journal of Ophthalmology

Volumn 100, Issue 6, 2016, Pages 782-786

  Miserocchi, Elisabetta ^a   Modorati, Giulio ^a   Berchicci, Luigi ^a   Pontikaki, Irene ^b   Meroni, Pierluigi ^b   Gerloni, Valeria ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; ARTICLE; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPIRETINAL MEMBRANE; EYE DISEASE; EYE SYNECHIA; FEMALE; GLAUCOMA; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KERATOPATHY; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PHTHISIS BULBI; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; UVEITIS; VISUAL ACUITY; YOUNG ADULT; ARTHRITIS, JUVENILE; COMPLICATION; DOSE RESPONSE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ARTHRITIS, JUVENILE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84942134606     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-306790     Document Type: Article

References (24)

1. Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology 2009;116:1544-51.
2. Carvounis PE, Herman DC, Cha S, et al. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefe's Arch Clin Exp Ophthalmol 2006;244:281-90.
3. Gregory AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study. Ophthalmology 2013;120:186-92.
4. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol 2006;34:365-74.
5. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-α blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-50.
6. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24.
7. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:860-4.
8. Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow up data from the Italian Registry. J Rheumatol 2013;40:74-9.
9. Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2013;7:1-6.
10. Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008;67:1145-52.
11. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006;2:20-7.
12. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50.
13. Freidlin J, Wong IG, Acharya N. Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol 2007;91:1414.
14. Corrish KS, Kuffova L, Forrester JV. Treatment of diffuse subretinal fibrosis uveitis with rituximab. Br J Ophthalmol 2015;99:153-4.
15. Joshi L, Lightman SL, Salama AD, et al. Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 2011;118:2498-503.
16. Miserocchi E, Pontikaki I, Modorati G, et al. Rituximab for uveitis. Ophthalmology 2011;118:223-4.
17. Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011;11:35-9.
18. Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011;50:1390-4.
19. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
20. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first International workshop. Am J Ophthalmol 2005;140:509-16.
21. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73.
22. Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 2002;109:137-42.
23. Barnes MG, Grom AA, Thompson SD, et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2102-12.
24. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.